---
layout: post
title: "近150亿“天量”成交！15倍新冠检测大牛股演绎“天地板” 机构游资激烈博弈"
date: 2022-04-15 19:12:04 +0800
categories: emnews
tags: 东财滚动新闻
---
> 新冠检测概念股大牛股九安医疗大幅高开后触及涨停，一度拿下四连板并刷新历史新高，但随后逐级下探，尾盘触及跌停且收盘封死跌停，上演“天地板”一幕。全天成交金额高达149亿元，换手率35%。（财联社）

<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><img src="https://webquotepic.eastmoney.com/GetPic.aspx?nid=0.002432&imageType=r&token=28dfeb41d35cc81d84b4664d7c23c49f" border="0" alt="R图 002432_0" data-code="R 002432|0|2" data-code2="R 002432|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></p><!-- EM_StockImg_End --><p>新冠检测概念股大牛股<span id="stock_0.002432"><a href="http://quote.eastmoney.com/unify/r/0.002432" class="keytip" data-code="0,002432">九安医疗</a></span><span id="quote_0.002432"></span>大幅高开后触及涨停，一度拿下四连板并<strong>刷新历史新高</strong>，但随后逐级下探，尾盘触及跌停且收盘封死跌停，<strong>上演“天地板”一幕</strong>。全天<strong>成交金额高达149亿元</strong>，换手率35%。<br /></p><center><img src="https://dfscdn.dfcfw.com/download/D24917667840876991136_w830h304.jpg" alt="image" width="580" emheight="212" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p><span web="1" href="http://quote.eastmoney.com/unify/r/0.002432" class="em_stock_key_common" data-code="0,002432">九安医疗</span>炸裂的一季报预告是股价近期飙涨的催化剂，昨晚同属新冠检测概念的两家A股公司也纷纷报喜。<span id="stock_1.688399"><a href="http://quote.eastmoney.com/unify/r/1.688399" class="keytip" data-code="1,688399">硕世生物</a></span><span id="quote_1.688399"></span>昨晚<span id="Info.3332"><a href="http://data.eastmoney.com/notices/" class="infokey">公告</a></span>，2021年净利同比增45.59%，拟10派100元，<strong><span id="Info.3276"><a href="http://data.eastmoney.com/yjfp/" class="infokey">分红</a></span>力度之大，暂列科创板第一</strong>，排在A股分红冠亚军<span id="stock_1.600519"><a href="http://quote.eastmoney.com/unify/r/1.600519" class="keytip" data-code="1,600519">贵州茅台</a></span><span id="quote_1.600519"></span>、<span id="stock_1.603444"><a href="http://quote.eastmoney.com/unify/r/1.603444" class="keytip" data-code="1,603444">吉比特</a></span><span id="quote_1.603444"></span>之后<strong>排名第三</strong>。<span id="stock_1.688575"><a href="http://quote.eastmoney.com/unify/r/1.688575" class="keytip" data-code="1,688575">亚辉龙</a></span><span id="quote_1.688575"></span>则公告，预计2022年Q1归母<span id="Info.3324"><a href="http://data.eastmoney.com/bbsj/" class="infokey">净利润</a></span>为4.5亿元至5亿元，<strong>同比增加1094.75%至1227.5%</strong>。</p><p>从股价表现来看，<span web="1" href="http://quote.eastmoney.com/unify/r/1.688575" class="em_stock_key_common" data-code="1,688575">亚辉龙</span>大幅高开一度暴涨12%但尾盘接近翻绿；<span web="1" href="http://quote.eastmoney.com/unify/r/1.688399" class="em_stock_key_common" data-code="1,688399">硕世生物</span>更是低开且收盘大跌8%。</p><center><img src="https://dfscdn.dfcfw.com/download/D25183286243112911760_w830h303.jpg" alt="image" width="580" emheight="212" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><center><img src="https://dfscdn.dfcfw.com/download/D25638701806239522627_w831h310.jpg" alt="image" width="580" emheight="216" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p>午后，针对今日市场有关“<strong><span id="stock_1.600104"><a href="http://quote.eastmoney.com/unify/r/1.600104" class="keytip" data-code="1,600104">上汽集团</a></span><span id="quote_1.600104"></span>将于4月18日启动复工复产压力测试</strong>”的传闻，<span web="1" href="http://quote.eastmoney.com/unify/r/1.600104" class="em_stock_key_common" data-code="1,600104">上汽集团</span>回应财联社记者表示，当前先按照政府要求配合做好防疫，同时养护改造设备，<strong>周密做好满足防疫条件下生产的相关准备工作</strong>。</p><p>市场人士分析，随着新冠检测公司<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>纷纷披露，<strong>利好预期已充分反应在相关上市公司股价</strong>上，A股<strong>历来利好出尽是利空的博弈情绪很浓</strong>。另外，<strong>午后复工复产消息的扰动更是引发疫情受益相关股票的进一步回落</strong>。</p><p>背后是哪些资金在“<strong>疯狂出逃</strong>”？<span web="1" href="http://quote.eastmoney.com/unify/r/0.002432" class="em_stock_key_common" data-code="0,002432">九安医疗</span>盘后公布的一日榜数据显示，<span id="Info.321"><a href="http://data.eastmoney.com/stock/lhb.html" class="infokey">龙虎榜</a></span>资金净卖出1.55亿元。<strong>机构专用位列买二、买三和卖五席位</strong>。有<strong>“散户大本营”之称的<span id="stock_0.300059"><a href="http://quote.eastmoney.com/unify/r/0.300059" class="keytip" data-code="0,300059">东方财富</a></span><span id="quote_0.300059"></span><span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>拉萨营业部位列买五席位</strong>。顶级游资<span id="stock_1.600030"><a href="http://quote.eastmoney.com/unify/r/1.600030" class="keytip" data-code="1,600030">中信证券</a></span><span id="quote_1.600030"></span>西安朱雀大街位列买一和卖三席位；知名游资<span id="stock_1.601211"><a href="http://quote.eastmoney.com/unify/r/1.601211" class="keytip" data-code="1,601211">国泰君安</a></span><span id="quote_1.601211"></span><span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>北京朱春路、华鑫<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>深圳益田路位列卖一和卖四席位。</p><center><img src="https://dfscdn.dfcfw.com/download/D25611146411251515148_w831h423.jpg" alt="image" width="580" emheight="295" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p>拉长时间来看，九安医疗股价自2021年11月低点至今，<strong>股价累计最高涨幅最达1519.6%</strong>。</p><center><img src="https://dfscdn.dfcfw.com/download/D25456149300672679029_w830h378.jpg" alt="image" width="580" emheight="264" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p>从所属的新冠检测板块来看，九安医疗年初至今涨幅达63.67%，<strong>位列涨幅排行榜第一</strong>。</p><center><img src="https://dfscdn.dfcfw.com/download/D24890469865799661678_w609h469.jpg" alt="image" width="580" emheight="447" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p>4月12日，九安医疗公告，<strong>一季度预计净利润为140亿元—160亿元，比上年同期增长36707.43%—41965.63%</strong>。公告指出，受美国疫情发展的影响，当地对新冠抗原检测试剂盒产品需求大幅增长。从净利润增速来看，九安医疗预计净利润增幅排名两市第一，<strong>暂列“预增王”</strong>。</p><p>在过去一个月，国内已有<span id="stock_0.300482"><a href="http://quote.eastmoney.com/unify/r/0.300482" class="keytip" data-code="0,300482">万孚生物</a></span><span id="quote_0.300482"></span>、<span id="stock_1.688068"><a href="http://quote.eastmoney.com/unify/r/1.688068" class="keytip" data-code="1,688068">热景生物</a></span><span id="quote_1.688068"></span>、<span id="stock_1.688298"><a href="http://quote.eastmoney.com/unify/r/1.688298" class="keytip" data-code="1,688298">东方生物</a></span><span id="quote_1.688298"></span>等<strong>20余家公司的新冠抗原检测产品获批上市</strong>，而且多地开始启动新冠抗原产品的集采，价格已经低至5元/人份，<strong>业内普遍认为国内市场会进入薄利多销的状态</strong>。</p><p>业内人士分析称，随着与ACC合作订单的持续回款，二季度虽可能延续涨势，但九安ihealth在美获批后，<strong>FDA又接连批准了多家用新冠抗原检测试剂，市场竞争必然会渐次激烈</strong>。</p><p class="em_media">（文章来源：财联社）</p>

<http://finance.eastmoney.com/news/1345,202204152345312576.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)